What are Difference between Myasthenia Gravis and Multiple Sclerosis?

Feature

Myasthenia gravis

Multiple sclerosis

Type of Disease

Autoimmune neuromuscular disorder

Autoimmune demyelinating disorder of the central nervous system

Main Problem

Impaired communication between nerves and muscles

Damage to myelin sheath around nerve fibers in brain and spinal cord

Cause

Antibodies attack acetylcholine receptors at the neuromuscular junction

Immune system attacks myelin in CNS (brain, spinal cord, optic nerves)

Key Symptoms

Muscle weakness that worsens with activity (fatigue), drooping eyelids (ptosis), double vision (diplopia), difficulty swallowing or breathing

Numbness, weakness, balance problems, vision issues, cognitive changes, muscle spasticity

Pattern

Fluctuating weakness (worse with use, better with rest)

Relapsing-remitting or progressive decline

Areas Affected

Voluntary (skeletal) muscles

CNS (brain, spinal cord, optic nerves)

Onset

Often sudden and fluctuates daily

Can be gradual, with periods of worsening and partial recovery

Age of Onset

Any age, often young adults or middle-aged women

Young adults (20–40 years most common)

Diagnosis

Antibody blood tests (AChR, MuSK), EMG, Tensilon test

MRI brain/spinal cord, lumbar puncture (CSF analysis), evoked potentials

Treatment

Acetylcholinesterase inhibitors (like pyridostigmine), immunosuppressants, plasmapheresis, IVIG

Steroids, disease-modifying therapies (like interferons, monoclonal antibodies), symptomatic treatments

Prognosis

Variable; many manage symptoms well with treatment
 

Variable; can be mild to disabling depending on disease course

Feature

Multiple Sclerosis

Myasthenia Gravis

Location of Damage

Central Nervous System (CNS) — brain, spinal cord, optic nerves

Neuromuscular Junction — where nerve endings meet muscles

Problem Type

Damage to the myelin sheath that insulates nerve fibers → slows or blocks nerve signals inside the CNS

Blockage of signal transmission from nerve to muscle due to antibodies attacking receptors

Effect on Nerves

Nerve fibers themselves become scarred ("sclerosis") and miscommunicate internally

Nerves are normal; the problem is at the connection to muscles (external to CNS)

Type of Symptoms

Sensory loss (numbness, tingling), weakness, visual disturbances, cognitive issues, spasticity

Fluctuating muscle weakness, especially with repeated use (e.g., drooping eyelids, trouble chewing, breathing weakness)

Nerve Signal

Slowed or distorted inside the brain and spinal cord

Fails at the junction where the nerve meets the muscle

Multiple Sclerosis

Myasthenia Gravis

Main Symptom

Sensory changes (numbness, tingling), weakness, vision loss, balance problems, spastic muscles

Muscle weakness that gets worse with use — especially eyes (drooping eyelids, double vision), face, swallowing, breathing

Fatigue Pattern

General tiredness and nerve damage over time

Muscle fatigue that worsens with repeated activity, improves with rest

Areas Most Affected

Brain, spinal cord, optic nerves

Muscles controlled by voluntary movement (especially eyes, face, throat, limbs)

Onset

Often gradual, sometimes sudden attack (relapse)

Sudden muscle weakness, often noticeable after physical activity

Unique Clues

Vision loss in one eye (optic neuritis), electric shock feeling with neck movement (Lhermitte's sign)

Eyelid drooping (ptosis) and double vision that worsens throughout the day

Tests to Diagnose

MRI brain/spinal cord, lumbar puncture (CSF), evoked potentials

Blood test for AChR or MuSK antibodies, EMG (repetitive nerve stimulation), Tensilon test

Response to Treatment

Steroids and MS disease-modifying therapies

Rapid improvement after acetylcholinesterase inhibitors (like pyridostigmine)

MS

MG

Main Treatment Goal

Slow disease progression, reduce relapses, manage symptoms

Improve muscle strength, prevent myasthenic crises

Medications for Core Disease

Disease-Modifying Therapies (DMTs):
- Interferons (e.g., Avonex, Rebif)
- Monoclonal antibodies (e.g., ocrelizumab, natalizumab)
- Oral drugs (e.g., fingolimod, dimethyl fumarate)

Acetylcholinesterase Inhibitors:
- Pyridostigmine (Mestinon) to improve communication between nerves and muscles

Steroids Use

Used during relapses to reduce inflammation (e.g., IV methylprednisolone)

Used during severe weakness or myasthenic crisis

Immunosuppresants

Sometimes used (e.g., azathioprine, methotrexate) if MS is aggressive

Commonly used (e.g., prednisone, azathioprine, mycophenolate mofetil) to lower antibody attack

Emergency Treatments

High-dose steroids for MS flare-ups

Plasmapheresis (plasma exchange) or IVIG (intravenous immunoglobulin) for myasthenic crisis

Surgery

Not usually needed

Thymectomy (removal of the thymus gland) — helps some MG patients

Lifestyle Management

Physical therapy, occupational therapy, managing fatigue and temperature sensitivity

Energy conservation techniques, physical therapy focused on maintaining muscle strength without overfatiguing

Prognosis with Treatment

Can slow progression significantly; some live almost normal lives

Good symptom control for most patients; crisis can be prevented with treatment